Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06122766 · ClinicalTrials.gov registry record

NGLY1 Natural History

A clinical trial, sponsored by Baylor College of Medicine.

Completed
Registry status
15
Enrollment target

NCT06122766 is a clinical trial that has completed, run by Baylor College of Medicine. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06122766 has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
15 participants
Enrollment target

Study Summary

N-glycanase 1 (NGLY1) Deficiency (OMIM #615273) is an ultra-rare, autosomal recessive disorder caused by loss of function variants in NGLY1 gene. The multisystemic disorder is characterized by five key features: (1) global developmental delay and/or intellectual disability, (2) a (primarily) hyperkinetic movement disorder (3) transient elevation of liver transaminases (4) (hypo)- alacrima and (5) peripheral neuropathy. The condition was first reported in 2012 and thus comprehensive characterization of the disease, especially its unique movement disorder, continues to be described. The hyperkinetic movement disorder in NGLY1 Deficiency is highly complex and has been qualitatively described to include choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements. These descriptors apply to both lower and upper limb movement in individuals with NGLY1 Deficiency. Preliminary results indicate that NGLY1 Deficiency is associated with a myriad of movement control problems and range from being unable to perform certain arm movements or walk to behaviors that appear quite similar to age-matched neurotypical individuals. Preliminary results suggest that when reaching for objects, arm motion patterns tend to display unusual joint and hand trajectories, relative to neurotypical individuals, thereby decreasing their effectiveness/efficiency. During gait, range of joint motion, particularly at the knee, was often significantly reduced combined with evidence of leg movement asymmetry. Additionally, preliminary results indicate that there is low frequency tremor, particularly in the upper limbs, that tends to decline during arm acceleration. These preliminary findings, if confirmed in a larger sample, provide entryways to the understanding of how NGLY1 Deficiency impacts movement control and thereby may serve both as diagnostic and therapeutic endpoints for physicians and therapists. The purpose of this natural history study in NGLY1 Deficiency is to collect

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-02-27
Est. Completion 2024-10-24

Sponsor

Baylor College of Medicine

616 total trials

What the Registry Record Tells You About NCT06122766

The ClinicalTrials.gov registry entry for NCT06122766 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT06122766 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06122766 about?

NCT06122766 is a clinical study titled "NGLY1 Natural History". N-glycanase 1 (NGLY1) Deficiency (OMIM #615273) is an ultra-rare, autosomal recessive disorder caused by loss of function variants in NGLY1 gene. The multisystemic disorder is characterized by five key features: (1) global developmental delay and/or intellectual disability, (2) a (primarily) hyperki...

What is the current status of trial NCT06122766?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2023-02-27. Estimated completion is 2024-10-24.

Who is sponsoring clinical trial NCT06122766?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.